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8LETTER TO THE EDITOR
wenty-Year Follow-Up of a Controlled Trial
omparing a Combination of Methotrexate Plus
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iBetween August 9, 1983, and April 10, 1985, we
onducted a controlled trial that compared the safety
nd efﬁcacy of a combination of methotrexate plus
yclosporine with cyclosporine alone for preventing
cute graft-versus-host disease (GVHD) in 93 patients
dministered HLA-identical sibling marrow grafts for
he treatment of acute myelogenous leukemia (AML;
 48) in ﬁrst remission and chronic myelocytic
eukemia (CML; n  45) in chronic phase [1]. We
ound that methotrexate/cyclosporine-treated patients
ad less grade II to III acute GVHD (32% versus
9%; P  .01) compared with cyclosporine-treated
atients, and no patient given the combination devel-
ped grade IV acute GVHD, compared with 7 cyclo-
porine-treated patients. Early survival was improved
n patients given methotrexate/cyclosporine. The cur-
ent report updates the results of the trial with a
edian follow-up of 20 years (range, 10-21 years).
atients were conditioned for transplantation by high
oses of cyclophosphamide and total body irradiation.
etails on patient characteristics, conditioning, and
mmunosuppressive regimens and methods of ran-
omization were described in the original article [1].
Results are summarized in Figure 1. Methotrex-
te/cyclosporine-treated patients experienced a 26%
robability of nonrelapse mortality, compared with
6% for cyclosporine-treated patients (P  .07). The
elapse rates among methotrexate/cyclosporine-treated
atients and cyclosporine-treated patients were compa-
able, which was true for both CML (4% versus 7%; P
55) and AML (29% versus 19%; P  .62) patients,
espectively. Patients with CML administered meth-
trexate/cyclosporine had trends for better overall and
isease-free survival compared with patients adminis-
ered cyclosporine alone (P  .08 for each), whereas
verall and disease-free survival curves were compa-
able for both study arms among patients with AML
P  .64 and .74, respectively). All surviving patients
ave experienced remissions of their underlying leu- s
14emias. The prevalence curves [2] describing the onset
f clinical extensive chronic GVHD and its resolution
n response to therapy for both CML and AML pa-
ients were comparable for the 2 study arms (P  .66).
rgan involvements with chronic GVHD in the cy-
losporine versus methotrexate/cyclosporine arms in-
luded skin (13 versus 13 patients), liver (9 versus 7
atients), gut (1 versus 1 patient), oral sicca (11 versus
patients), and ocular sicca (12 versus 12 patients).
or the cyclosporine-alone arm, the prevalence of
hronic GVHD peaked at 1.1 years, reaching 33%,
nd the combination methotrexate/cyclosporine arm
eached 29% at 1.1 years, peaking at 30% at 2.1 years.
y 20 years after marrow grafting, the prevalence of
hronic GVHD was 4% and 12% for the single-drug
nd combination arms, respectively.
We examined the effect of acute or chronic
VHD (ﬁrst occurrence of either) on overall and
isease-free survivals by using time-dependent covari-
tes in a Cox proportional hazards model. This was
one while adjusting for the study arms, which were
ot signiﬁcant once the effect of GVHD was included
s a factor. In all patients, the hazard ratios of GVHD,
hile adjusting for the study arms, were 2.5 (95%
onﬁdence interval [CI], 1.2, 5.2) and 2.6 (95% CI,
.2, 5.4) for predicting overall and disease-free surviv-
ls, respectively. Among the AML patients, the hazard
atios of GVHD for predicting overall and disease-
ree survivals were the same (1.6; 95% CI, 0.6, 3.9),
hereas for the CML patients, the hazard ratios of
VHD were 5.0 (95% CI, 1.4, 18.3) for overall sur-
ival and 5.1 (95% CI, 1.4, 18.6) for disease-free
urvival.
We conclude that patients treated with metho-
rexate/cyclosporine had a signiﬁcantly decreased in-
idence and severity of acute GVHD. After a median
ollow-up of 20 years, there was a suggestion for
mprovement of survival, but this beneﬁt was re-
tricted to the subgroup of patients with CML.
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cyclosporine; MTX, methotrexate.
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